Seattle startup lands $12.7M for AI-designed multi-target proteins
A Seattle biotech startup has secured $12.7 million and partnerships with pharmaceutical giants Pfizer and Kite Pharma. The company uses AI to design proteins that can bind multiple cellular targets at once, potentially creating more effective treatments.